According to the report, the source did not specify the effectiveness of the AZ vaccine against the Brazilian variant of the virus, but stressed that full results are expected within the month.
The Fiocruz Foundation, the Brazilian public health research institute that provided Oxford with the study samples, said it had no knowledge of the study, saying it was led by Astellicom and Oxford. Neither unit responded to Reuters’ request for comment.
In addition, early results also showed that the AZ vaccine was significantly less effective against the South African variant, which is actually very similar to the Brazilian variant, and the vaccine was subsequently suspended in South Africa.
Epidemiologists have pointed to the Brazilian variant as one of the factors contributing to the recent increase in the number of diagnoses and deaths in Brazil, and the scientific community has been concerned about the efficacy of the vaccine.
Recent Comments